Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 704

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 704
---
 |    |     | Class B Ordinary 
 Shares           |           |     |        |     |     | Accumulated |            |   |     | Shareholders’ |            |   |
|                                                                                                    |     | Shares                               |         |     | Amount |    |     | Shares           |           |     | Amount |     |     | Deficit     |            |   |     | Deficit       |            |   |
| Balance as of December 31, 2022                                                                    |     |                                      | 510,000 |     | $      | 51 |     |                  | 2,062,500 |     | $      | 206 |     | $           | (3,271,562 | ) |     | $             | (3,271,305 | ) |
| Net income                                                                                         |     |                                      |       — |     |        |  — |     |                  |         — |     |        |   — |     |             |    632,536 |   |     |               |    632,536 |   |
| Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust 
 account and extension deposit)                                                                     |     |                                      |       — |     |        |  — |     |                  |         — |     |        |   — |     |             | (5,643,271 | ) |     |               | (5,643,271 | ) |
| Balance as of December 31, 2023                                                                    |     |                                      | 510,000 |     | $      | 51 |     |                  | 2,062,500 |     | $      | 206 |     | $           | (8,282,297 | ) |     | $             | (8,282,040 | ) |

The accompanying notes are an integral part of these consolidated financial statements. F-8

DENALI CAPITAL ACQUISITION CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS

|                                                                                      |     | For the     
 Year Ended  
 December 31 
 2024        |             |   |     | For the      
 Year Ended   
 December 31, 
 2023         |             |   |
|:-------------------------------------------------------------------------------------|:----|:------------|------------:|:--|:----|:-------------|------------:|:--|
| Cash flows from operating activities:                                                |     |             |             |   |